Cite
Fernández A, Navarro-Zapata A, Escudero A, et al. Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy. Cancers (Basel). 2021;13(3)doi: 10.3390/cancers13030577.
Fernández, A., Navarro-Zapata, A., Escudero, A., Matamala, N., Ruz-Caracuel, B., Mirones, I., Pernas, A., Cobo, M., Casado, G., Lanzarot, D., Rodríguez-Antolín, C., Vela, M., Ferreras, C., Mestre, C., Viejo, A., Leivas, A., Martínez, J., Fernández, L., & Pérez-Martínez, A. (2021). Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy. Cancers, 13(3), . https://doi.org/10.3390/cancers13030577
Fernández, Adrián, et al. "Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy." Cancers vol. 13,3 (2021). doi: https://doi.org/10.3390/cancers13030577
Fernández A, Navarro-Zapata A, Escudero A, Matamala N, Ruz-Caracuel B, Mirones I, Pernas A, Cobo M, Casado G, Lanzarot D, Rodríguez-Antolín C, Vela M, Ferreras C, Mestre C, Viejo A, Leivas A, Martínez J, Fernández L, Pérez-Martínez A. Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy. Cancers (Basel). 2021 Feb 02;13(3). doi: 10.3390/cancers13030577. PMID: 33540698; PMCID: PMC7867223.
Copy
Download .nbib